NCT03658785: Immunotherapy for the Treatment of Advanced Solid Tumor

NCT03658785
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic and/or untreated brain metastases; Patients who have received prior treatment with immunotherapy
https://ClinicalTrials.gov/show/NCT03658785

Comments are closed.

Up ↑